EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis

Jong-Wook Lee, Hyeon-Soo Ahn, Jinho Chang, Hye-Young Kang, Dong-Jin Chang, Jae Kyung Suh, Hankil Lee

Korean Journal of Ophthalmology · 05.10.2022 · 36 (5) · 423-434

DOI: 10.3341/kjo.2022.0061 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Korean Journal of Ophthalmology, erschienen am 05.10.2022. Verfasst von Jong-Wook Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, Korea. Hauptthemen laut MEDLINE: Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension, Prostaglandins F, Synthetic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Netarsudil is a Rho kinase inhibitor and the first new class of clinically useful ocular hypotensive agents. In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma.

Methods

We identified relevant studies in PubMed, Ovid Medline, Embase, and Cochrane Central until April 2021. The quality of the studies and the level of evidence were assessed using the Risk of Bias tool. Efficacy was measured as the mean difference in reducing intraocular pressure (IOP), and safety was assessed by the risk of conjunctival hyperemia (CH) due to FDC therapy, netarsudil monotherapy, or latanoprost monotherapy.

Results

Four studies met the predefined eligibility criteria and were included in the meta-analysis. The mean difference in the reduction in IOP after 2 weeks and 4 to 6 weeks of drug administration was -2.41 mmHg (95% confidence interval [CI], -2.95 to -1.87) and -1.77 mmHg (95% CI, -2.31 to -1.87), respectively, in patients receiving FDC therapy versus those receiving latanoprost monotherapy. On the other hand, latanoprost monotherapy had a greater effect in reducing IOP than netarsudil monotherapy after 4 to 6 weeks of administration (mean difference, 0.95 mmHg; 95% CI, 0.43 to 1.47). The risk of CH was significantly higher with both FDC therapy and netarsudil monotherapy compared to latanoprost monotherapy in week 12, where the relative ratio was 3.01 (95% CI, 1.95 to 4.66) and 2.33 (95% CI, 1.54 to 3.54), each.

Conclusions

Netarsudil/latanoprost FDC therapy has a significantly greater effect on reducing IOP than latanoprost alone. The symptoms of CH were mostly mild, and only a few glaucoma patients discontinued the medication owing to CH in earlier clinical trials. Therefore, it would be beneficial to consider the administration of netarsudil/latanoprost FDC therapy in patients with glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaGlaucoma, Open-AngleOcular HypertensionProstaglandins F, SyntheticAntihypertensive AgentsBenzoatesHumansIntraocular PressureLatanoprostTimololTreatment Outcomebeta-Alaninerho-Associated Kinases

Stichwörter der Autor:innen

GlaucomaIntraocular pressureLatanoprostMeta-analysisRho-associated kinases

Substanzen

Antihypertensive AgentsBenzoatesProstaglandins F, Syntheticbeta-AlanineLatanoprostTimololrho-Associated Kinasesnetarsudil

Autor:innen und Institutionen

  • Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, Korea.
  • Yonsei Institute of Pharmaceutical Sciences, Yonsei University College of Pharmacy, Incheon, Korea.
  • Department of Pharmaceutical Medicine and Regulatory Sciences, Yonsei University College of Medicine, Incheon, Korea.
  • Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • National Evidence-based Healthcare Collaboration Agency, Seoul, Korea.
  • Ajou University College of Pharmacy, Suwon, Korea.

Zitieren

APA

Lee, J. W., Ahn, H. S., Chang, J., Kang, H. Y., Chang, D. J., Suh, J. K., & Lee, H. (2022). Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Korean Journal of Ophthalmology, 36(5), 423-434. https://doi.org/10.3341/kjo.2022.0061

Vancouver

Lee JW, Ahn HS, Chang J, Kang HY, Chang DJ, Suh JK, et al. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Korean Journal of Ophthalmology. 2022;36(5):423-434. doi:10.3341/kjo.2022.0061

BibTeX
@article{Lee2022,
  author = {Lee, Jong-Wook and Ahn, Hyeon-Soo and Chang, Jinho and Kang, Hye-Young and Chang, Dong-Jin and Suh, Jae Kyung and Lee, Hankil},
  title = {Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis},
  journal = {Korean Journal of Ophthalmology},
  year = {2022},
  volume = {36},
  number = {5},
  pages = {423--434},
  doi = {10.3341/kjo.2022.0061}
}
Kostenlos starten →